RAYALDEE has been witnessing decent momentum, courtesy of successful efforts from the sales team.The company expects the BioReference R&D pipeline to increase throughout 2019, backed by improving cash flows from Bio-Reference and RAYALDEE.OPKO Healthâ€™s focus on R&D is a positive factor.The same for earnings stands at a loss of 43 cents per share.Stocks to ConsiderSome better-ranked stocks in the broader medical space are Cerner Corporation CERN, HealthEquity, Inc. HQY and Chegg, Inc. CHGG, each carrying a Zacks Rank #2 (Buy).